We can’t show the full text here under this license. Use the link below to read it at the source.
Difference in the effects of switching from Candesartan to Olmesartan or Telmisartan to Olmesartan in hypertensive patients with type 2 diabetes: the COTO study
Comparing the effects of switching from candesartan or telmisartan to olmesartan in people with high blood pressure and type 2 diabetes
AI simplified
Abstract
Switching to olmesartan resulted in a significant decrease in clinic blood pressure and morning home blood pressure in hypertensive patients with type 2 diabetes.
- A total of 165 patients switched from candesartan and 152 from telmisartan participated in the study.
- Clinic blood pressure, morning home diastolic blood pressure, and urinary albumin levels decreased significantly after 16 weeks of olmesartan treatment.
- Morning home systolic blood pressure also showed a significant reduction with olmesartan compared to baseline.
- After switching back to candesartan or telmisartan, there was a significant increase in clinic blood pressure, morning home blood pressure, and urinary albumin levels.
- No adverse reactions requiring withdrawal from the study were reported, and no adverse reactions attributable to the drugs were observed.
AI simplified
Key numbers
20.6±6.1 mg/g Cr
Urinary Albumin Decrease
Decrease in urinary albumin in the CO group after olmesartan treatment.
74.5%
Target BP Achievement Rate Increase
Achievement rate for target clinic BP in the CO group at week 16 of olmesartan treatment.
Significant decrease
Morning Home BP Decrease
Morning home BP significantly decreased after 16 weeks of olmesartan treatment.